Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...

The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...

Overactive bladder (OAB) is associated with arthritis, with a positive association seen after adjustment for all covariates.